GLUCAGON-LIKE PEPTIDE-1 PROMOTES SATIETY AND SUPPRESSES ENERGY-INTAKEIN HUMANS

We examined the effect of intravenously infused glucagonlike peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed break fast, and on spontaneous energy intake at an ad libitum lunch. 20 youn g, healthy, normal-weight men participated in a placebo-controlled, ra ndomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/kg.h or s aline) was started simultaneously with initiation of the test meals. V isual analogue scales were used to assess appetite sensations througho ut the experiment and the palatability of the test meals. Blood was sa mpled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced sati ety and fullness compared with placebo (treatment effect: P < 0.03). F urthermore, spontaneous energy intake at the ad libitum lunch was redu ced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected sig nificantly by the treatment (P < 0.002). In conclusion, the results sh ow that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energ y intake in humans.